The nuclear receptor TLX (NR2E1) inhibits growth and progression of triple- negative breast cancer.

ABSTRACT: Development of targeted therapies will be a critical step towards reducing the mortality associated with triple-negative breast cancer (TNBC). To achieve this, we searched for targets that met three criteria: (1) pharmacologically targetable, (2) expressed in TNBC, and (3) expression is prognostic in TNBC patients. Since nuclear receptors have a well-defined ligand-binding domain and are thus highly amenable to small-molecule intervention, we focused on this class of protein. Our analysis identified TLX (NR2E1) as a candidate. Specifically, elevated tumoral TLX expression was associated with prolonged recurrence-free survival and overall survival for breast cancer patients with either estrogen receptor alpha (ERα)-negative or basal-like tumors. Using two TNBC cell lines, we found that stab

SUBMITTER: Nelczyk AT 

PROVIDER: S-EPMC9983295 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature